Headquartered in Acton, MA Fiscal year ends December NASDAQ: PODD insulet.com
Insulet Corporation is a medical device company focused on simplifying diabetes management through its Omnipod product platform. The Omnipod Insulin Management System is a tubeless, wearable, disposable insulin delivery pod that provides up to three days of continuous insulin delivery without needles. The company's flagship product, the Omnipod 5 Automated Insulin Delivery System, integrates with continuous glucose monitors to automate blood sugar management and can be controlled via a compatible personal smartphone or dedicated controller. Insulet sells Omnipod products in 26 countries, with Omnipod 5 available in 20 countries. The company is advancing its pipeline with the next-generation Omnipod 6 and fully closed-loop technology for type 2 diabetes. Insulet also leverages its Pod technology platform for non-insulin subcutaneous drug delivery across other therapeutic areas through its Drug Delivery segment, though this remains a small portion of revenue. Updated
Wall Street analysts made some dramatic moves on Thursday, slashing price targets by double digits on several high-profile names while upgrading others to buy. Find out which stocks got the most surprising…
Pre-Market Stock Futures: The futures are trading lower on Tuesday, but another week and another set of new highs for the S&P 500 and the Nasdaq, as AI fever overshadowed Iran’s peace…
Pre-Market Stock Futures: Futures are trading mixed as we get set to close out a wild week on Wall Street that saw a little bit of everything served with a massive helping…
Pre-Market Stock Futures: Futures are trading lower on Tuesday morning after investors returned from the three-day Easter weekend to find a stock market ready to rally after some promising news on the…
Pre-Market Stock Futures: Futures are trading mixed after a solid start to the week, with all the major indices, except the Russell 2000, finishing the day higher. Anticipation of earnings reports from…
Tuesday's top analyst upgrades and downgrades included AppLovin, Block, ConocoPhillips, Datadog, FedEx, Nvidia, Okta, PayPal, Rivian Automotive, Toast and Zscaler.
Monday's top analyst upgrades and downgrades included Altice USA, Arista Networks, Block, Cardinal Health, ConocoPhillips, Datadog, GoodRx, Monster Beverage, PepsiCo, Spirit AeroSystems, Twilio and WeWork.
Tuesday's top analyst upgrades and downgrades included Airbnb, American Express, Fastly, JPMorgan Chase, Mattel, Nike, Realty Income, Redfin, Southwestern Energy and Zillow.
Friday's top analyst upgrades and downgrades included Agnico-Eagle Mines, Biogen, Exelon, Meta Platforms, New York Times, PulteGroup, Snap and Vertex Pharmaceutical.
Thursday's top analyst upgrades and downgrades included Advanced Micro Devices, Beyond Meat, Colgate-Palmolive, Edwards Lifesciences, Electronic Arts, Exxon Mobil, Meta Platforms, PayPal and Starbucks.
Thursday's top analyst upgrades and downgrades included Carnival, Dow, Goldman Sachs, Micron Technology, Netflix, Oracle, Snap, Spotify and Twitter.
Friday's top analyst upgrades and downgrades included Bill.com, CenterPoint Energy, CommScope, Herbalife, Hyatt Hotels, Motorola Solutions, Murphy Oil, Trade Desk and Vonage.
Friday's top analyst upgrades and downgrades included Arch Coal, AT&T, Delphi Technologies, Domino's Pizza, Dunkin Brands, Expedia, Illumina, Kinder Morgan, Oceaneering International, Splunk and Workday.
Thursday's top analyst upgrades, downgrades and initiations included Abbott Laboratories, Alexion Pharmaceuticals, Avis Budget, DexCom, Johnson & Johnson, Marvell Technology, Moderna, Snap, Splunk and Zoom Video Communications.
Friday's top analyst upgrades, downgrades and initiations included Ambarella, Apple, Comcast, Costco, CSX, Domino's, Dish Network, Etsy, HP, 3M, Nike, PepsiCo and Snap.
Insulet Corporation is a medical device company focused on simplifying diabetes management through its Omnipod product platform. The Omnipod Insulin Management System is a tubeless, wearable, disposable insulin delivery pod that provides up to three days of continuous insulin delivery without needles.
24/7 Wall St.'s 12-month price target for PODD is $176.50, rated Buy. The Wall Street consensus target is $171.91. PODD price prediction →
